New anxiety pill shows promise in major trial

NCT ID NCT06809595

Ongoing Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times

Summary

This study tests an oral medication called MM120 against a placebo in 245 adults with generalized anxiety disorder. Participants take the drug or placebo for 12 weeks, and those who complete may join a 40-week follow-up where everyone gets the active drug. The goal is to see if MM120 reduces anxiety symptoms more than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

4 Medical Clinical Solutions

London, United Kingdom
4 Medical Clinical Solutions

Manchester, United Kingdom
A-shine s.r.o.

Pilsen, Czechia
Adams Clinical Boston

Boston, Massachusetts, 02116, United States
Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Austin Clinical Trial Partners

Austin, Texas, 78737, United States
Bradenton Research Center, Inc.

Bradenton, Florida, 34205, United States
CMME

Paris, France
Cabinet Dr.Desbonnet : Résidence Saint Michel

Douai, France
Cedar Clinical Research

Murray, Utah, 84107, United States
Central Institute of Mental Health

Mannheim, Germany
Centre Hospitalier du Rouvray

Sotteville-lès-Rouen, France
Centrum Badan Klinicznych PI-House sp. z o.o.

Gdansk, Poland
Clerkenwell Health

London, United Kingdom
Clerkenwell Health - Baker Street

London, United Kingdom
Clinical Neuroscience Solutions, Inc

Orlando, Florida, 32801, United States
Core Clinical Research

Everett, Washington, 98201, United States
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital

Gosforth, United Kingdom
Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz

Lodz, Poland
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin

Berlin, Germany
Department of Psychiatry, UCK

Gdansk, Poland
GHU Paris Psychiatrie et Neurosciences

Paris, France
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage

Marseille, France
Institut Neuropsychiatricke Pece (INEP)

Prague, Czechia
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie

Tübingen, Germany
Neuro-Behavioral Clinical Research, Inc.

North Canton, Ohio, 44720, United States
Neuroclin Glasgow

Glasgow, United Kingdom
OVID Clinic Berlin

Berlin, Germany
Preferred Research Partners, Inc.

Little Rock, Arkansas, 72211, United States
Princeton Medical Institute

Princeton, New Jersey, 08540, United States
Psychedelic Science Institute

Los Angeles, California, 90004, United States
Psyon s.r.o.

Prague, Czechia
Sheppard Pratt Health System

Towson, Maryland, 21204, United States
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital

London, United Kingdom
St George's Community Health Centre

Sheffield, United Kingdom
University of Cincinnati Psychiatry- Anxiety Disorders Research Program

Cincinnati, Ohio, 45219, United States
West Los Angeles VA Medical Center

Los Angeles, California, 90073, United States

Conditions

The condition(s) this trial relates to.

generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED ANXIETY DISORDER GENERALIZED ANXIETY DISORDER